Last reviewed · How we verify
NCT04724031
Real World Data Analysis of PARP Inhibitors Use in Patients With Ovarian Cancer
trial testing PARP inhibitor in Ovarian Cancer in 150 participants. Status unknown.
30 June 2021
Quick facts
| Lead sponsor | Hellenic Cooperative Oncology Group |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 150 |
| Start date | 1 November 2019 |
| Primary completion | 30 June 2021 |
| Estimated completion | 30 September 2023 |
| Sites | 1 location across Greece |
Drugs / interventions tested
- PARP inhibitor — full drug profile →
Conditions studied
- Ovarian Cancer — all drugs for Ovarian Cancer →
Sponsor
Hellenic Cooperative Oncology Group
Who can join
Adults 18 to 80, female only, with Ovarian Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Real-world clinical outcomes and toxicity data will be evaluated in patients with advanced high grade ovarian cancer who will receive PARP inhibitors.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04724031
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of PARP inhibitor
Trials testing the same drug.
- NCT07472140 — PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombination Deficie · Phase 2, PHASE3 · recruiting
- NCT06145308 — Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing · Phase 2 · recruiting
- NCT05392686 — PD1 and PARP for Maintenance Therapy in NSLLC · Phase 2 · unknown
- NCT04774627 — Pancytopenia Related to PARP Inhibitors (PancytoRIB) · completed
- NCT05406999 — Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer · Phase 2 · recruiting
Other recruiting trials for Ovarian Cancer
Currently open trials in the same condition.
- NCT06412120 — Study Evaluating Safety, Tolerability, and Metabolism of Niraparib · Phase 4 · recruiting
- NCT06930755 — Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer · Phase 1 · recruiting
- NCT07318558 — A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021) · Phase 3 · recruiting
- NCT07491081 — EARLY Study: Evaluating the Specificity and Feasibility of the EARLY Biomarker Panel for Ovarian Cancer Detection · NA · recruiting
- NCT07410676 — EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
Other Hellenic Cooperative Oncology Group trials
Trials by the same sponsor.
- NCT07528911 — Elements of Adaptive Immunity in Epithelial Ovarian Cancer · completed
- NCT06504719 — Safety and Efficacy Real-world Data of Trastuzumab Deruxtecan and Sacituzumab Govitecan · completed
- NCT04985058 — Real-world Data in Patients With Breast Cancer Treated With Abemaciclib · recruiting
- NCT04632173 — Head and Neck cancERs International cOviD-19 collabOraTion · unknown
- NCT04745377 — Responses to COVID-19 Vaccination in Patients With Cancer · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04724031 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hellenic Cooperative Oncology Group
- Last refreshed: 14 March 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04724031.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing